Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Core Laboratories Inc. /DE/

Accession: 0001193125-26-436200

Filed: 2026-10-28

Period: 2026-10-28

CIK: 0001958086

SIC: 1389 (OIL, GAS FIELD SERVICES, NBC)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — clb-20261028.htm (Primary)

EX-99.1 (clb-ex99_1.htm)

GRAPHIC (img77179564_0.gif)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: clb-20261028.htm · Sequence: 1

8-K

false000195808600019580862026-10-282026-10-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2026

CORE LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41695

98-1164194

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

6316 Windfern Road

Houston, TX

77040

(Address of principal executive offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (713) 328-2673

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock (par value $0.01)

CLB

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 28, 2026, Core Laboratories Inc. issued a press release announcing its financial results for the third quarter of 2026.

Item 7.01 Regulation FD Disclosure.

On October 28, 2026, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on November 9, 2026 and payable November 30, 2026.

The full text of the press release is set forth in Exhibit 99.1 attached hereto.

The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly stated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

99.1 Press release issued on October 28, 2026 *

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

* This exhibit is intended to be furnished and shall not be deemed “filed” for purposes of the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Core Laboratories Inc.

Dated: October 28, 2026

By

/s/ Christopher S. Hill

Christopher S. Hill

Chief Financial Officer

EX-99.1

EX-99.1

Filename: clb-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

CORE LAB REPORTS THIRD QUARTER 2026 RESULTS:

•

REVENUE OF $132.1 MILLION, UP 6% SEQUENTIALLY AND DOWN 2% YEAR-OVER-YEAR

•

OPERATING INCOME OF $12.1 MILLION; EX-ITEMS, $12.6 MILLION, UP 35% SEQUENTIALLY AND DOWN 24% YEAR-OVER-YEAR

•

GAAP EARNINGS PER SHARE OF $0.12; EPS EX-ITEMS OF $0.16, UP 46% SEQUENTIALLY AND DOWN 27% YEAR-OVER-YEAR

•

FREE CASH FLOW OF $1.7 MILLION

•

COMPANY REPURCHASED 87,873 SHARES OF COMMON STOCK, FOR $1.1 MILLION AGGREGATE PURCHASE PRICE

•

COMPANY ANNOUNCES Q4 2026 QUARTERLY DIVIDEND

HOUSTON (October 28, 2026)—Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported third quarter 2026 revenue of $132,100,000. Core’s operating income was $12,100,000, with earnings per diluted share (“EPS”) of $0.12, all in accordance with U.S. generally accepted accounting principles ("GAAP"). Operating income, ex-items, a non-GAAP financial measure, was $12,600,000, yielding operating margins of 10% with sequential incremental margins of 43%, and EPS, ex-items, of $0.16. A full reconciliation of non-GAAP financial measures is included in the attached financial tables.

Core’s CEO, Larry Bruno, stated, “Our third quarter results delivered sequential revenue growth across both of our operating segments. International revenue was up in Europe-Africa, Asia-Pacific, Latin America, and the Middle East. There was a gradual improvement in activity in the Middle East, particularly late in the quarter. Improving demand across these international regions drove Reservoir Description revenue higher during the quarter, just above the top end of our guidance range. Production Enhancement’s revenue growth was led by strong U.S. product sales, which benefited from modestly improved U.S. land completion activity and increased adoption of our proprietary completion technologies. International product sales also strengthened sequentially.

Looking at the mid to long term, we see our key international regions positioned for growth, including long-cycle offshore exploration and appraisal projects. Face-to-face meetings with clients throughout Asia-Pacific during the third quarter reinforced our view that the region is entering a period of sustained activity growth, with projects advancing across both conventional and unconventional plays. Core Lab's established global network has the Company well-positioned to support these programs. Although geopolitical conflicts in the Middle East and Russia-Ukraine still affect portions of our business, we are encouraged by improving demand and project momentum across our global client base.”

Reservoir Description

Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately 80% of revenue sourced from projects originating outside the United States. Revenue for Reservoir Description in the third quarter of 2026 was $84,300,000, up 7% sequentially and down 4% year-over-year. Operating income on a GAAP basis was $7,700,000. Operating income, ex-items, was $8,100,000, yielding operating margins of 10% and strong sequential incremental margins of 78%.

Sequential revenue growth was driven by increased international demand for the Company's laboratory services, led by project work in Europe-Africa, Asia-Pacific, Latin America and the Middle East. Demand for assay services in the Middle East showed modest improvement late in the quarter but remained below pre-conflict levels. Ongoing geopolitical instability and associated sanctions in the Middle East and Russia-Ukraine continued to weigh on demand for these services.

During the third quarter of 2026, following the successful completion of an initial reservoir characterization study, a leading national oil company in the Middle East awarded Core Lab an expanded analytical program to evaluate its unconventional reservoirs. The initial study combined Core’s proprietary technologies and integrated laboratory workflows to determine reservoir quality and fluid saturations. The expanded program will utilize Core Lab’s PRISM™ workflow, together with the Company’s proprietary High Frequency NMR, NANO-k™ 100 Nano Permeametry, and Shale Matrix Permeameter (“SMP-200™”) technologies. By integrating these laboratory measurements with other petrophysical and geological data, Core Lab is characterizing rock properties and fluid saturations, while also differentiating movable and immovable hydrocarbons. These datasets will assist the operator in evaluating hydrocarbon production potential and support development planning.

Also, during the third quarter of 2026, Omega Oil and Gas engaged Core’s team to evaluate more than 360 feet of conventional core and sidewall cores from two appraisal wells in Queensland’s Taroom Trough in the Bowen Basin. High-quality whole core recovered from multiple hydrocarbon-bearing stratigraphic horizons are undergoing a comprehensive reservoir characterization program at Core Lab’s Advanced Technology Center in Perth, Australia. Upon arrival at the laboratory, the cores were scanned using the Company’s proprietary, non-invasive Dual Energy Computed Tomography technology. This technology provides early lithologic and petrophysical data to support the operator’s initial assessment of potential pay intervals ahead of traditional physical laboratory measurements. The ongoing analytical program will combine these datasets to characterize reservoir quality and calibrate well logs, supporting Omega’s appraisal of the resource. Core Lab is pleased to be assisting Omega Oil and Gas and its technical experts in the evaluation of this emerging play.

Production Enhancement

Production Enhancement operations, which are focused on complex completions in unconventional and conventional oil and gas reservoirs in the U.S., as well as projects across the globe, posted third quarter 2026 revenue of $47,800,000, up 4% sequentially and 3% year-over-year. Operating income for the third quarter on a GAAP basis was $4,300,000. Operating income, ex-items, was $4,400,000, yielding operating margins of 9%.

Sequential revenue growth was led by product sales, which rose 14%, with increases in both U.S. land and international markets. In the U.S., sales benefited from increased demand for the Company's completion products and growing adoption of its proprietary completion technologies. International product sales grew across Europe, Asia-Pacific and the Middle East. These gains were partially offset by the timing of diagnostic service activity in the Gulf of America, as several large projects originally scheduled for the third quarter were delayed, impacting both revenue and operating margins.

During the third quarter of 2026, a North American oilfield service company engaged Core Lab to enhance the efficiency and precision of its perforating operations. Core supplied its proprietary AERO FLEX™, AERO POINT™, and AERO SET™ technologies, together with field implementation support. The integrated AERO™ platform enabled the client to configure perforating assemblies for varying well requirements, simplifying assembly and redress procedures, and precisely orienting perforating charges within the wellbore. These engineered capabilities reduce preparation time and improve placement accuracy while supporting more consistent execution across multiple completion programs. Following successful field deployment, the client is expanding adoption of the AERO™ product family throughout its North American operations.

Also during the third quarter, a Brazilian independent oil and gas operator focused on revitalizing mature onshore fields engaged Core Lab to support a waterflood optimization project. To improve sweep efficiency, the operator implemented a polymer treatment followed by a conventional waterflood traced with Core’s proprietary SpectraFlood™ technology. Analysis of produced water samples collected across the field showed delayed tracer breakthrough, indicating the polymer treatment was effective in slowing flood-front movement as intended. Given these results, the operator is expanding its use of Core Lab’s flood diagnostic technology throughout its portfolio of more than 50 conventional assets, enhancing revenue opportunities for the Company in South America.

Liquidity, Free Cash Flow, Share Repurchases, and Dividend

Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the third quarter of 2026, cash from operations was $5,000,000, and capital expenditures associated with operations were $3,300,000, yielding FCF of $1,700,000. Certain raw materials used in the manufacturing of perforating systems have increased the cost of carrying inventory. Additionally, activity for both operating segments increased as we exited the third quarter of 2026, resulting in a higher level of accounts receivable at the end of the quarter. These two factors resulted in an increase of working capital as of September 30, 2026.

As previously disclosed, a fire in February 2024 damaged a building at Core Lab's Advanced Technology Center in Aberdeen, Scotland, and the related losses are covered by the Company's property and casualty insurance. Insurance proceeds, along with capital expenditures to replace equipment and restore the building, are reported separately within investing activities in the cash flow statement and are excluded from the calculation of FCF. These capital expenditures were approximately $500,000 in the third quarter of 2026.

In the third quarter of 2026, Core Lab repurchased 87,873 shares at an aggregate purchase price of approximately $1,100,000.

As of September 30, 2026, Core’s net debt (defined as long-term debt less cash and cash equivalents) was $93,400,000, a reduction of $200,000. Also during the third quarter of 2026, the Company’s leverage ratio (calculated as total net debt divided by trailing twelve months adjusted EBITDA) was under 1.50. The Company remains focused on executing its strategic initiatives and continues to evaluate the allocation of capital between debt reduction and other uses of free cash that return value to shareholders.

On July 29, 2026, Core’s Board of Directors ("Board") announced a quarterly cash dividend of $0.01 per share of common stock, which was paid on August 31, 2026, to shareholders of record on August 10, 2026.

On October 28, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on November 30, 2026, to shareholders of record on November 9, 2026.

Return on Invested Capital

The Board and the Company's executive management remain focused on strategies that maximize return on invested capital ("ROIC") and FCF, measures the Company believes are closely correlated with total shareholder return. Core's asset-light business model and disciplined approach to capital allocation are intended to promote capital efficiency and deliver superior, more predictable ROIC over the long term.

The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield services companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg’s formula, Core Lab’s ROIC for the third quarter of 2026 was 5.9%.

Industry and Core Lab Outlook and Guidance

Ongoing geopolitical conflicts in the Middle East and Russia-Ukraine, along with associated sanctions, continued to disrupt the transportation and trading of crude oil and refined products during the third quarter of 2026. Although cargo traffic through the Strait of Hormuz gradually improved late in the third quarter, crude oil supply remained significantly disrupted, creating near-term volatility in commodity prices and uncertainty around the timing of upstream client activity. These geopolitical events also impacted upstream operations and slowed the pace of client projects.

Higher energy prices and constrained availability of certain petroleum products have weighed on crude oil demand in the near term. Looking ahead, the IEA, EIA and OPEC all anticipate strong global crude oil demand growth in 2027 as supply disruptions ease and trade flows normalize. Short-cycle U.S. onshore activity is more sensitive to crude oil price volatility, while large-scale international projects are expected to be more resilient and proceed as planned, unless directly impacted by regional conflicts. Overall, the Company believes the historic disruption to the global supply of oil and gas caused by the Middle East conflict will support improved activity in 2027, and a long-term growth cycle for oilfield services. Natural production declines from existing fields, the need to rebuild depleted global inventories, and clients’ increasing focus on reserve replacement, underscores the importance of investment in new sources of

production and in maximizing recovery from existing fields. Core Lab’s reservoir characterization and production optimization technologies support operators in evaluating new resources, reducing development risk, and improving recovery from producing reservoirs.

For the fourth quarter of 2026, Core Lab expects revenue to remain relatively flat sequentially, reflecting continued disruptions in the Middle East. Early in the fourth quarter, attacks affected client operations in the region and have already resulted in some project delays.

In the U.S., Core expects the customary year-end seasonal moderation in land completion activity, partially offset by sequential improvement in diagnostic services. A sequential increase in Production Enhancement service activity is expected to drive growth quarter over quarter.

Although recovery in certain Middle East countries remains difficult to predict, Core Lab’s international laboratory network, proprietary technologies, and specialized expertise position the Company to capitalize on emerging opportunities across global markets.

Reservoir Description’s fourth quarter 2026 revenue is projected to range from $81,000,000 to $85,000,000, with operating income of $5,100,000 to $8,300,000. Production Enhancement’s fourth quarter revenue is estimated to range from $47,500,000 to $49,500,000, with operating income of $5,500,000 to $6,700,000. Core’s fourth quarter 2026 revenue is projected to range from $128,500,000 to $134,500,000, with operating income of $10,700,000 to $15,100,000, yielding operating margins of approximately 10%. EPS for the fourth quarter of 2026 is expected to be $0.12 to $0.20.

The Company’s guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange, and assumes an effective tax rate of 25%.

Earnings Call Scheduled

The Company has scheduled a conference call to discuss Core's third quarter 2026 earnings announcement. The call will begin at 7:30 a.m. CDT / 8:30 a.m. EDT on Thursday, October 29, 2026. To access the listen-only webcast, visit www.corelab.com/investors 15 minutes before the start of the call. For those not available to listen to the live webcast, a replay and transcript will be available on the Company’s website shortly after the call. Analysts may contact investor.relations@corelab.com for conference call dial-in information.

Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements Core Lab makes, includes forward-looking statements regarding the Company’s future revenue, profitability, business strategies and developments, demand for the Company’s products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the impact of tariffs, supply chain disruptions, trade policies and sanctions, international civil unrest or geopolitical tensions, including the continuing armed conflict between Russia and Ukraine, escalation of

military conflict between the United States, Israel and Iran, and political conditions in South America, most recently in Venezuela, severe weather events, the severity and duration of public health crises, and any related actions taken by businesses and governments, and other factors as more fully described in the Company's most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. These important factors could cause the Company's actual results to differ materially from those described in these forward-looking statements. Such statements are based on current expectations of the Company's performance and are subject to a variety of factors, some of which are not under the control of the Company. Because the information herein is based solely on data currently available, and because it is subject to change as a result of changes in conditions over which the Company has no control or influence, such forward-looking statements should not be viewed as assurance regarding the Company's future performance.

The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.

Visit the Company's website at www.corelab.com.

For more information, contact:

Gwen Gresham - SVP Corporate Development and Investor Relations

Phone: +1 713 328 6210

E-mail: investor.relations@corelab.com

CORE LABORATORIES INC. & SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended

% Variance

September 30,

2026

June 30,

2026

September 30,

2025

vs. Q2-26

vs. Q3-25

REVENUE

$

132,077

$

124,609

$

134,521

6.0%

(1.8)%

OPERATING EXPENSES:

Costs of services and product sales

105,092

101,371

104,901

3.7%

0.2%

General and administrative expense

11,268

10,953

10,688

2.9%

5.4%

Depreciation and amortization

3,724

3,825

3,594

(2.6)%

3.6%

Other (income) expense, net

(72

)

(691

)

(5,590

)

NM

NM

Total operating expenses

120,012

115,458

113,593

3.9%

5.7%

OPERATING INCOME

12,065

9,151

20,928

31.8%

(42.3)%

Interest expense

2,786

2,846

2,650

(2.1)%

5.1%

Income before income taxes

9,279

6,305

18,278

47.2%

(49.2)%

Income tax expense

3,816

507

3,754

652.7%

1.7%

Net income

5,463

5,798

14,524

NM

(62.4)%

Net income (loss) attributable to non-controlling interest

19

(158

)

285

NM

NM

Net income attributable to Core Laboratories Inc.

$

5,444

$

5,956

$

14,239

(8.6)%

(61.8)%

Diluted earnings per share

$

0.12

$

0.12

$

0.31

—%

(61.3)%

Diluted earnings per share attributable to Core Laboratories Inc.

$

0.12

$

0.13

$

0.30

(7.7)%

(60.0)%

Diluted weighted average common shares outstanding

46,711

46,878

47,078

(0.4)%

(0.8)%

Effective tax rate

41

%

8

%

21

%

NM

NM

SEGMENT INFORMATION:

Revenue:

Reservoir Description

$

84,318

$

78,747

$

88,224

7.1%

(4.4)%

Production Enhancement

47,759

45,862

46,297

4.1%

3.2%

Consolidated

$

132,077

$

124,609

$

134,521

6.0%

(1.8)%

Operating income:

Reservoir Description

$

7,703

$

3,678

$

16,574

109.4%

(53.5)%

Production Enhancement

4,327

5,228

4,379

(17.2)%

(1.2)%

Corporate and Other

35

245

(25

)

NM

NM

Consolidated

$

12,065

$

9,151

$

20,928

31.8%

(42.3)%

"NM" means not meaningful

CORE LABORATORIES INC. & SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Nine Months Ended September 30,

% Variance

2026

2025

REVENUE

$378,483

$388,265

(2.5)%

OPERATING EXPENSES:

Costs of services and product sales

308,536

308,071

0.2%

General and administrative expense

36,939

34,799

6.1%

Depreciation and amortization

11,313

10,981

3.0%

Other (income) expense, net

(1,408)

(6,222)

NM

Total operating expenses

355,380

347,629

2.2%

OPERATING INCOME

23,103

40,636

(43.1)%

Interest expense

8,523

7,963

7.0%

Income before income taxes

14,580

32,673

(55.4)%

Income tax expense

4,072

7,411

(45.1)%

Net income

10,508

25,262

(58.4)%

Net income (loss) attributable to non-controlling interest

(103)

541

NM

Net income attributable to Core Laboratories Inc.

$10,611

$24,721

(57.1)%

Diluted earnings per share

$0.22

$0.53

(58.5)%

Diluted earnings per share attributable to Core Laboratories Inc.

$0.23

$0.52

(55.8)%

Diluted weighted average common shares outstanding

46,883

47,381

(1.1)%

Effective tax rate

28%

23%

NM

SEGMENT INFORMATION:

Revenue:

Reservoir Description

$244,996

$255,401

(4.1)%

Production Enhancement

133,487

132,864

0.5%

Total

$378,483

$388,265

(2.5)%

Operating income:

Reservoir Description

$12,527

$31,116

(59.7)%

Production Enhancement

10,359

9,030

14.7%

Corporate and Other

217

490

NM

Total

$23,103

$40,636

(43.1)%

"NM" means not meaningful

CORE LABORATORIES INC. & SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

% Variance

ASSETS:

September 30,

2026

June 30,

2026

December 31,

2025

vs. Q2-26

vs. Q4-25

Cash and cash equivalents

$

21,376

$

22,735

$

22,702

(6.0)%

(5.8)%

Accounts receivable, net

115,573

108,817

113,528

6.2%

1.8%

Inventories

60,699

57,961

54,496

4.7%

11.4%

Other current assets

27,407

24,847

23,939

10.3%

14.5%

Total current assets

225,055

214,360

214,665

5.0%

4.8%

Property, plant and equipment, net

100,840

100,390

99,447

0.4%

1.4%

Right of use assets

51,145

52,870

54,346

(3.3)%

(5.9)%

Intangibles, goodwill and other long-term assets, net

216,478

219,158

215,552

(1.2)%

0.4%

Total assets

$

593,518

$

586,778

$

584,010

1.1%

1.6%

LIABILITIES AND EQUITY:

Accounts payable

$

40,012

$

40,163

$

37,275

(0.4)%

7.3%

Short-term operating lease liabilities

11,718

11,940

11,456

(1.9)%

2.3%

Other current liabilities

51,002

48,947

57,284

4.2%

(11.0)%

Total current liabilities

102,732

101,050

106,015

1.7%

(3.1)%

Long-term debt, net

112,447

113,861

110,255

(1.2)%

2.0%

Long-term operating lease liabilities

37,806

39,314

42,309

(3.8)%

(10.6)%

Other long-term liabilities

56,443

53,784

53,223

4.9%

6.1%

Total equity

284,090

278,769

272,208

1.9%

4.4%

Total liabilities and equity

$

593,518

$

586,778

$

584,010

1.1%

1.6%

CORE LABORATORIES INC. & SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Nine Months Ended September 30,

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

$

10,508

$

25,262

Adjustments to reconcile net income to net cash provided by operating activities:

Stock-based compensation

7,218

6,023

Depreciation and amortization

11,313

10,981

Changes in value of life insurance policies

(1,251

)

(1,851

)

Deferred income taxes

1,232

(4,573

)

Accounts receivable

(2,179

)

(615

)

Inventories

(6,822

)

(1,268

)

Accounts payable

2,674

1,284

Accrued expenses

(3,598

)

(3,370

)

Other adjustments to net income

(2,352

)

(2,788

)

Net cash provided by operating activities

16,743

29,085

CASH FLOWS FROM INVESTING ACTIVITIES:

Capital expenditures - operations

(11,381

)

(8,265

)

Capital expenditures - rebuilding of Aberdeen facility

(2,990

)

(2,672

)

Net proceeds from insurance recovery

139

9,951

Acquisitions, net of cash acquired

—

(617

)

Proceeds from sale of assets

3,144

2,348

Net proceeds on life insurance policies

557

778

Other investing activities

18

(2

)

Net cash provided by (used in) investing activities

(10,513

)

1,521

CASH FLOWS FROM FINANCING ACTIVITIES:

Repayment of long-term debt

(93,250

)

(47,000

)

Proceeds from long-term debt

95,000

36,000

Debt issuance costs

—

(1,706

)

Dividends paid

(1,379

)

(1,403

)

Repurchase of common stock

(7,740

)

(9,770

)

Other financing activities

(187

)

(255

)

Net cash used in financing activities

(7,556

)

(24,134

)

NET CHANGE IN CASH AND CASH EQUIVALENTS

(1,326

)

6,472

CASH AND CASH EQUIVALENTS, beginning of period

22,702

19,157

CASH AND CASH EQUIVALENTS, end of period

$

21,376

$

25,629

Non-GAAP Information

Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.

Reconciliation of Operating Income, Net Income and Diluted Earnings Per Share Attributable to Core Laboratories Inc.

(In thousands, except per share data)

(Unaudited)

Operating Income

Three Months Ended

September 30,

2026

June 30,

2026

September 30,

2025

GAAP reported

$

12,065

$

9,151

$

20,928

Inventory and asset write-downs, lease termination, other exit costs and severance (2)

—

—

601

Insurance recovery on property, plant and equipment (3)

—

—

(5,252

)

Foreign exchange losses (gains)

548

219

354

Excluding specific items

$

12,613

$

9,370

$

16,631

Net Income Attributable to Core Laboratories Inc.

Three Months Ended

September 30,

2026

June 30,

2026

September 30,

2025

GAAP reported

$

5,444

$

5,956

$

14,239

Inventory and asset write-downs, lease termination, other exit costs and severance (2)

—

—

451

Insurance recovery on property, plant and equipment (3)

—

—

(3,939

)

Foreign exchange losses (gains)

411

165

265

Effect of higher (lower) tax rate (4)

1,496

(1,070

)

(815

)

Excluding specific items

$

7,351

$

5,051

$

10,201

Diluted Earnings Per Share Attributable to Core Laboratories Inc.

Three Months Ended

Nine Months Ended

September 30,

2026

June 30,

2026

September 30,

2025

September 30,

2026

GAAP reported

$

0.12

$

0.13

$

0.30

$

0.23

Stock compensation (1)

—

—

—

0.06

Inventory and asset write-downs, lease termination, other exit costs and severance (2)

—

—

0.01

0.01

Insurance recovery on property, plant and equipment (3)

—

—

(0.08

)

—

Foreign exchange losses (gains)

0.01

—

0.01

0.01

Effect of higher (lower) tax rate (4)

0.03

(0.02

)

(0.02

)

0.01

Excluding specific items

$

0.16

$

0.11

$

0.22

$

0.32

(1) The nine months ended September 30, 2026 includes the acceleration of stock compensation expense associated with employees reaching eligible retirement age.

(2) The nine months ended September 30, 2026 includes the write-down of leasehold improvements and lease exit costs. The three months ended September 30, 2025 includes write-down of inventory.

(3) The three months ended September 30, 2025 includes an insurance recovery associated with the fire at the Aberdeen, U.K. facility.

(4) The three months ended September 30 and June 30, 2026 and September 30, 2025 reflect tax expense at a normalized rate of 25%.

Segment Information

(In thousands)

(Unaudited)

Operating Income

Three Months Ended September 30, 2026

Reservoir Description

Production Enhancement

Corporate and Other

GAAP reported

$

7,703

$

4,327

$

35

Foreign exchange losses (gains)

393

69

86

Excluding specific items

$

8,096

$

4,396

$

121

Return on Invested Capital

Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.

ROIC of 5.9% is defined by Bloomberg as Net Operating Profit After Tax ("NOPAT") of $23.4 million divided by Average Total Invested Capital ("Average TIC") of $397.2 million, where NOPAT is defined as GAAP net income before non-controlling interest plus the sum of income tax expense, interest expense, and pension expense, less the sum of pension service cost and tax effect on income before interest and tax expense for the last four quarters. Average TIC is defined as the average of beginning and ending periods' GAAP stockholders' equity, plus the sum of net long-term debt, lease liabilities, and allowance for credit losses, net of deferred taxes and income taxes payable.

Free Cash Flow

Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures - operations. Management believes that free cash flow provides useful information to investors regarding the cash available in the period in excess of Core’s needs to fund its capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash does not represent residual cash available for distribution because Core may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.

Computation of Free Cash Flow

(In thousands)

(Unaudited)

Three Months Ended

Nine Months Ended

September 30, 2026

September 30, 2026

Net cash provided by operating activities

$

4,969

$

16,743

Capital expenditures - operations

(3,246

)

(11,381

)

Free cash flow

$

1,723

$

5,362

###

GRAPHIC

GRAPHIC

Filename: img77179564_0.gif · Sequence: 3

Binary file (218099 bytes)

Download img77179564_0.gif

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.3

Document And Entity Information

Oct. 28, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 28, 2026

Entity Registrant Name

CORE LABORATORIES INC.

Entity Tax Identification Number

98-1164194

Entity Central Index Key

0001958086

Entity Emerging Growth Company

false

Entity File Number

001-41695

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Address, Address Line One

6316 Windfern Road

Entity Address, City or Town

Houston

Entity Address, State or Province

TX

City Area Code

713

Local Phone Number

328-2673

Entity Incorporation, State or Country Code

DE

Entity Address, Postal Zip Code

77040

Title of 12(b) Security

Common Stock (par value $0.01)

Trading Symbol

CLB

Security Exchange Name

NYSE

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration